卡塔尔哈马德总医院他汀类药物治疗患者横纹肌溶解的频率

Abdelmonem B. Yousif, Ebtihal B. Hassan, M. Ahmed, Mona Lashin, Neathu Kunjumon, T. Sulaiman, Maram Saliba, A. Shier, Mona Babikir, Walaa A. H. Saeed, A. Farghaly, F. Khan
{"title":"卡塔尔哈马德总医院他汀类药物治疗患者横纹肌溶解的频率","authors":"Abdelmonem B. Yousif, Ebtihal B. Hassan, M. Ahmed, Mona Lashin, Neathu Kunjumon, T. Sulaiman, Maram Saliba, A. Shier, Mona Babikir, Walaa A. H. Saeed, A. Farghaly, F. Khan","doi":"10.4103/ljms.ljms_13_21","DOIUrl":null,"url":null,"abstract":"Background: Statins are well tolerated but associated with various statin-associated symptoms, including statin-associated rhabdomyolysis. Objectives: The aim of this study was to evaluate the frequency of rhabdomyolysis in patients treated with various statins and to describe their clinical features and outcomes in our local setting. Patients and Methods: This retrospective cross-sectional study was conducted at Hamad General Hospital and included all patients who received statins for the period between January 1, 2017, and November 31, 2017. Results: Out of 1000 cases involved in this study, 3 cases (0.3%) met the criteria for rhabdomyolysis. Two of them were males and the third was a female. Two cases received simvastatin and one case received rosuvastatin. All developed muscle pain and were hospitalized, during which all patients were treated with drug withdrawal and hydration. Upon discharge, rosuvastatin was replaced by atorvastatin, while simvastatins were replaced by atorvastatin and rosuvastatin. Conclusion: Rhabdomyolysis is a recognized but rare side effect of statins that should not be a reason to limit the use of life-saving statin therapy.","PeriodicalId":18055,"journal":{"name":"Libyan Journal of Medical Sciences","volume":"15 1","pages":"75 - 78"},"PeriodicalIF":0.0000,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Frequency of rhabdomyolysis in patients treated with statins in hamad general hospital, Qatar\",\"authors\":\"Abdelmonem B. Yousif, Ebtihal B. Hassan, M. Ahmed, Mona Lashin, Neathu Kunjumon, T. Sulaiman, Maram Saliba, A. Shier, Mona Babikir, Walaa A. H. Saeed, A. Farghaly, F. Khan\",\"doi\":\"10.4103/ljms.ljms_13_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Statins are well tolerated but associated with various statin-associated symptoms, including statin-associated rhabdomyolysis. Objectives: The aim of this study was to evaluate the frequency of rhabdomyolysis in patients treated with various statins and to describe their clinical features and outcomes in our local setting. Patients and Methods: This retrospective cross-sectional study was conducted at Hamad General Hospital and included all patients who received statins for the period between January 1, 2017, and November 31, 2017. Results: Out of 1000 cases involved in this study, 3 cases (0.3%) met the criteria for rhabdomyolysis. Two of them were males and the third was a female. Two cases received simvastatin and one case received rosuvastatin. All developed muscle pain and were hospitalized, during which all patients were treated with drug withdrawal and hydration. Upon discharge, rosuvastatin was replaced by atorvastatin, while simvastatins were replaced by atorvastatin and rosuvastatin. Conclusion: Rhabdomyolysis is a recognized but rare side effect of statins that should not be a reason to limit the use of life-saving statin therapy.\",\"PeriodicalId\":18055,\"journal\":{\"name\":\"Libyan Journal of Medical Sciences\",\"volume\":\"15 1\",\"pages\":\"75 - 78\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Libyan Journal of Medical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ljms.ljms_13_21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Libyan Journal of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ljms.ljms_13_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

背景:他汀类药物耐受性良好,但与各种他汀类药物相关症状相关,包括他汀类药物相关的横纹肌溶解。目的:本研究的目的是评估接受各种他汀类药物治疗的患者横纹肌溶解的频率,并描述其临床特征和当地环境的结果。患者和方法:这项回顾性横断面研究在哈马德总医院进行,纳入了2017年1月1日至2017年11月31日期间接受他汀类药物治疗的所有患者。结果:在本研究的1000例病例中,有3例(0.3%)符合横纹肌溶解的标准。其中两名是男性,第三名是女性。辛伐他汀2例,瑞舒伐他汀1例。所有患者均出现肌肉疼痛并住院治疗,在此期间,所有患者均接受停药和水合治疗。出院时,瑞舒伐他汀改为阿托伐他汀,辛伐他汀改为阿托伐他汀和瑞舒伐他汀。结论:横纹肌溶解是他汀类药物公认但罕见的副作用,不应成为限制使用他汀类药物治疗的理由。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Frequency of rhabdomyolysis in patients treated with statins in hamad general hospital, Qatar
Background: Statins are well tolerated but associated with various statin-associated symptoms, including statin-associated rhabdomyolysis. Objectives: The aim of this study was to evaluate the frequency of rhabdomyolysis in patients treated with various statins and to describe their clinical features and outcomes in our local setting. Patients and Methods: This retrospective cross-sectional study was conducted at Hamad General Hospital and included all patients who received statins for the period between January 1, 2017, and November 31, 2017. Results: Out of 1000 cases involved in this study, 3 cases (0.3%) met the criteria for rhabdomyolysis. Two of them were males and the third was a female. Two cases received simvastatin and one case received rosuvastatin. All developed muscle pain and were hospitalized, during which all patients were treated with drug withdrawal and hydration. Upon discharge, rosuvastatin was replaced by atorvastatin, while simvastatins were replaced by atorvastatin and rosuvastatin. Conclusion: Rhabdomyolysis is a recognized but rare side effect of statins that should not be a reason to limit the use of life-saving statin therapy.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信